JP Morgan Chase
ENTA icon

JP Morgan Chase’s Enanta Pharmaceuticals ENTA Stock Holding History

JP Morgan Chase’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Sell
103,059
-9,905
-9% -$133K ﹤0.01% 4449
2025
Q4 		$1.78M Sell
112,964
-10,853
-9% -$138K ﹤0.01% 4168
2025
Q3 		$1.48M Sell
123,817
-6,616
-5% -$52.9K ﹤0.01% 4302
2025
Q2 		$986K Sell
130,433
-3,769
-3% -$22.7K ﹤0.01% 4390
2025
Q1 		$741K Sell
134,202
-28,911
-18% -$179K ﹤0.01% 4541
2024
Q4 		$938K Sell
163,113
-80,515
-33% -$772K ﹤0.01% 4682
2024
Q3 		$2.52M Buy
243,628
+85,082
+54% +$1.11M ﹤0.01% 3816
2024
Q2 		$2.06M Buy
158,546
+20,499
+15% +$277K ﹤0.01% 3768
2024
Q1 		$2.41M Sell
138,047
-12,774
-8% -$169K ﹤0.01% 3704
2023
Q4 		$1.42M Sell
150,821
-46,313
-23% -$432K ﹤0.01% 4091
2023
Q3 		$2.2M Buy
197,134
+14,176
+8% +$228K ﹤0.01% 3473
2023
Q2 		$3.92M Buy
182,958
+15,779
+9% +$465K ﹤0.01% 3065
2023
Q1 		$6.76M Sell
167,179
-14,360
-8% -$686K ﹤0.01% 2590
2022
Q4 		$8.45M Buy
181,539
+8,916
+5% +$406K ﹤0.01% 2401
2022
Q3 		$8.95M Sell
172,623
-5,031
-3% -$294K ﹤0.01% 2236
2022
Q2 		$8.4M Buy
177,654
+138,097
+349% +$7.49M ﹤0.01% 2309
2022
Q1 		$2.81M Buy
39,557
+2,302
+6% +$150K ﹤0.01% 3486
2021
Q4 		$2.79M Sell
37,255
-376
-1% -$29.5K ﹤0.01% 3565
2021
Q3 		$2.14M Sell
37,631
-294
-0.8% -$14.5K ﹤0.01% 3746
2021
Q2 		$1.67M Sell
37,925
-1,382
-4% -$67.7K ﹤0.01% 3927
2021
Q1 		$1.94M Sell
39,307
-4,946
-11% -$247K ﹤0.01% 3752
2020
Q4 		$1.86M Sell
44,253
-1,605
-3% -$70.6K ﹤0.01% 3528
2020
Q3 		$2.06M Sell
45,858
-1,398
-3% -$67.7K ﹤0.01% 3216
2020
Q2 		$2.37M Buy
47,256
+339
+0.7% +$17.5K ﹤0.01% 2998
2020
Q1 		$2.41M Sell
46,917
-9,475
-17% -$505K ﹤0.01% 2827
2019
Q4 		$3.48M Sell
56,392
-4,304
-7% -$267K ﹤0.01% 2972
2019
Q3 		$3.65M Sell
60,696
-48,489
-44% -$3.6M ﹤0.01% 2958
2019
Q2 		$9.15M Buy
109,185
+52,004
+91% +$4.68M ﹤0.01% 2174
2019
Q1 		$5.46M Sell
57,181
-20,516
-26% -$1.84M ﹤0.01% 2522
2018
Q4 		$5.5M Buy
77,697
+22,638
+41% +$1.74M ﹤0.01% 2501
2018
Q3 		$4.71M Sell
55,059
-13,414
-20% -$1.34M ﹤0.01% 2794
2018
Q2 		$7.94M Sell
68,473
-33,595
-33% -$3.35M ﹤0.01% 2328
2018
Q1 		$8.26M Sell
102,068
-64,219
-39% -$4.94M ﹤0.01% 2159
2017
Q4 		$9.76M Buy
166,287
+50,310
+43% +$2.52M ﹤0.01% 2149
2017
Q3 		$5.34M Sell
115,977
-22,913
-16% -$921K ﹤0.01% 2525
2017
Q2 		$5M Buy
138,890
+28,436
+26% +$910K ﹤0.01% 2473
2017
Q1 		$3.4M Sell
110,454
-27,292
-20% -$850K ﹤0.01% 2688
2016
Q4 		$4.62M Sell
137,746
-1,229
-0.9% -$35.2K ﹤0.01% 2525
2016
Q3 		$3.7M Buy
138,975
+138,785
+73,045% +$3.22M ﹤0.01% 2438
2016
Q2 		$4K Sell
190
-224
-54% -$5.86K ﹤0.01% 4481
2016
Q1 		$12K Buy
+414
New +$11.5K ﹤0.01% 4205
2015
Q2 		– Sell
-45,508
Closed -$1.39M – 4052
2015
Q1 		$1.39M Buy
+45,508
New +$1.77M ﹤0.01% 3044

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JP Morgan Chase's ENTA Position: Q1 2026 in Review

JP Morgan Chase reduced its Enanta Pharmaceuticals (ENTA) stake by 8.8% in Q1 2026, selling an estimated $133K and leaving 103,059 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4449.

JP Morgan Chase first reported a position in ENTA in Q1 2015 and has held it in 42 quarters since. The position peaked at $9.76M in Q4 2017. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • JP Morgan Chase held 103,059 shares of Enanta Pharmaceuticals worth $1.26M as of Q1 2026.
  • JP Morgan Chase sold 9,905 Enanta Pharmaceuticals shares in Q1 2026, an estimated $133K.
  • Enanta Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4449 holding.
  • JP Morgan Chase first reported a position in Enanta Pharmaceuticals in Q1 2015 and has held it in 42 quarters since.
  • JP Morgan Chase's Enanta Pharmaceuticals position peaked at $9.76M in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.